Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE MONTH OF MAY 2023

 

COMMISSION FILE NUMBER 001-34041

 

Evotec SE

(Translation of registrant’s name into English)

 

Essener Bogen 7

22419 Hamburg

Germany

Tel: [phone]

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

 

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

 

 

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

Explanatory Note

 

On May 09, 2023, Evotec SE issued an Ad-Hoc announcement stating that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. A copy of the Ad-Hoc announcement is attached as Exhibit 99.1 hereto. A copy of the accompanying press release is attached as Exhibit 99.2 hereto.

  

2

 

SIGNATURE

 

Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Evotec SE
	By:	/s/ Laetitia Rouxel
		Name: Laetitia Rouxel
		Title: Chief Financial Officer

 

Date: 9^th May 2023

 

3

  

EXHIBIT INDEX

 

Exhibit		Description of Exhibit
99.1		Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
99.2		Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing

 

4